Table 1.
Patient characteristics.
Fig 1.
Changes in free and acyl carnitine in plasma creatinine (A) and urine, as assessed by urinary creatinine (B) after starting lenvatinib treatment.
The box spans data between two quartiles (IQR, interquartile range), and the bold line represents the median. The ends of the whiskers represent the largest and smallest values that are not outliers. Outliers are values between 1.5 and 3 IQRs from the end of the box. * p < 0.05; versus baseline (Pre).
Fig 2.
Correlation between the change in plasma and urine free carnitine on day 7 after starting lenvatinib therapy.
r = 0.545, p = 0.013.
Fig 3.
Time profiles of the plasma acyl-to-free carnitine ratio after starting lenvatinib treatment.
The heavy line represents the mean with the standard error. AC/FC ratio, AC-to-FC ratio. * p < 0.05; versus baseline (Pre).
Fig 4.
Correlation between the plasma acyl-to-free carnitine ratio and the Brief Fatigue Inventory (BFI) for each patient between baseline (A) and day 14 (B) or 28 (C).
AC/FC ratio, AC-to-FC ratio; BFI, Brief Fatigue Inventory; ΔBFI, difference in the Brief Fatigue Inventory.
Fig 5.
Change in the Brief Fatigue Inventory and the plasma acyl-to-free carnitine (AC/FC) ratio among baseline, the day before levocarnitine supplementation, and 4 weeks after the supplementation.
The thick line represents the mean with the standard error. The solid line represents without a lenvatinib dose reduction, and the dotted line represents with a lenvatinib dose reduction. BFI, Brief Fatigue Inventory; AC/FC ratio, AC-to-FC ratio; * p < 0.05 versus the day before levocarnitine supplementation.